Frederik Cuperjani1, Lumturije Gashi2, Fisnik Kurshumliu1, Shemsedin Dreshaj3, Fitim Selimi1. 1. Thoracic Surgery Clinic, University Clinical Center Kosovo, Pristina, Kosovo. 2. Pathology Institute, University Clinical Center Kosovo, Pristina, Kosovo. 3. Infectious Diseases Clinic, University Clinical Center Kosovo, Pristina, Kosovo.
Abstract
BACKGROUND: The aim of this study was to investigate the immunohistochemical expression of ribosomal protein (RP) S6-pS240 in non-special type invasive breast cancer in relation to other prognostic markers and gain new insights to facilitate more individualized treatment. METHODS: The following clinical and histopathological parameters of 120 patients were determined: S6-pS240 expression, age, menopausal status, tumor size and grade, TNM stage, Nottingham Prognostic Index (NPI), lymph node stage, estrogen and progesterone receptor (ER/PR) expression, HER2/neu amplification, lymphovascular invasion, and proliferative index as measured by Ki-67. Treatment protocol and disease-free survival were evaluated accordingly. RESULTS: Significant positive correlations were seen between S6-pS240 expression and Ki-67 values (rho = 0.530, p < 0.001), and NPI (rho = 0.370, p < 0.001) and HER2/neu amplification (rho = 0.368, p < 0.001). A negative correlation was found between S6-pS240 and ER/PR expression (rho = 0.362, p < 0.001). Patients with negative RP S6-pS240 expression had significantly longer disease-free survival (log-rank test, p = 0.005). CONCLUSION: Immunohistochemical analysis of RP S6-pS240 is a valuable additional prognostic marker in patients with invasive breast cancer. Routine use of S6-pS240 immunohistochemistry is recommended.
BACKGROUND: The aim of this study was to investigate the immunohistochemical expression of ribosomal protein (RP) S6-pS240 in non-special type invasive breast cancer in relation to other prognostic markers and gain new insights to facilitate more individualized treatment. METHODS: The following clinical and histopathological parameters of 120 patients were determined: S6-pS240 expression, age, menopausal status, tumor size and grade, TNM stage, Nottingham Prognostic Index (NPI), lymph node stage, estrogen and progesterone receptor (ER/PR) expression, HER2/neu amplification, lymphovascular invasion, and proliferative index as measured by Ki-67. Treatment protocol and disease-free survival were evaluated accordingly. RESULTS: Significant positive correlations were seen between S6-pS240 expression and Ki-67 values (rho = 0.530, p < 0.001), and NPI (rho = 0.370, p < 0.001) and HER2/neu amplification (rho = 0.368, p < 0.001). A negative correlation was found between S6-pS240 and ER/PR expression (rho = 0.362, p < 0.001). Patients with negative RP S6-pS240 expression had significantly longer disease-free survival (log-rank test, p = 0.005). CONCLUSION: Immunohistochemical analysis of RP S6-pS240 is a valuable additional prognostic marker in patients with invasive breast cancer. Routine use of S6-pS240 immunohistochemistry is recommended.
Entities:
Keywords:
Breast cancer; Immunohistochemistry; Marker; Non-special type; Prognosis; Ribosomal protein S6-pS240
Authors: Emad A Rakha; Maysa E El-Sayed; Andrew H S Lee; Christopher W Elston; Matthew J Grainge; Zsolt Hodi; Roger W Blamey; Ian O Ellis Journal: J Clin Oncol Date: 2008-05-19 Impact factor: 44.544
Authors: J A van der Hage; L J C M van den Broek; C Legrand; P C Clahsen; C J A Bosch; E C Robanus-Maandag; C J H van de Velde; M J van de Vijver Journal: Br J Cancer Date: 2004-04-19 Impact factor: 7.640